Recovery, prevention, and performance are becoming everyday products.
Throne Raises $10M to Expand AI Toilet Diagnostics
Smart toilet startup Throne raised a $10M Series A to expand its AI-powered bathroom sensor beyond gut health.
- The device attaches to existing toilets, using computer vision to track bowel movements, hydration, and urinary patterns before delivering personalized insights through its app.
- The company also launched an AI gut health coach and says future versions could help detect early signs of colon cancer and other gastrointestinal diseases.
As continuous health monitoring goes mainstream, Throne is betting the bathroom is the next frontier for passive, always-on diagnostics.
Nike and Hyperice Turn Recovery Into Footwear
Nike and Hyperice unveiled the Air Zoom Hyperslide, a recovery sandal combining Nike’s Air Zoom cushioning with built-in heat and vibration therapy.
How it works: the slides deliver 15-minute treatment sessions through a removable module embedded in the strap, bringing Hyperice’s recovery technology into an everyday product.
Tapping a growing category, brands are embedding recovery directly into the products consumers already wear.
FDA Advisors Back Six Peptides
An FDA advisory committee voted to recommend allowing pharmacies to compound six peptides, including BPC-157, MOTS-c, TB-500, KPV, Semax, and Epitalon.
- The recommendation could create a legal pathway for prescription access to therapies that have largely existed in a gray market, but the FDA has final say.
- Supporters argue regulated access is safer than unregulated online sales, while critics say the evidence for many peptides remains too limited to justify broader availability.
Peptides have already become one of consumer wellness’s fastest-growing categories. Now, the FDA is deciding how they’ll be regulated and who gets to participate.
